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Trauma is a leading cause of death in pediatrics.
Currently, no medical treatment exists to reduce
mortality in the setting of pediatric trauma; however,
this evidence does exist in adults. Bleeding and
coagulopathy after trauma increases mortality in both
adults and children. Clinical research has demonstrated
a reduction in mortality with early use of tranexamic
acid in adult trauma patients in both civilian and military
settings. Tranexamic acid used in the perioperative
setting safely reduces transfusion requirements in
children. This article compares the hematologic
response to trauma between children and adults,
and explores the potential use of tranexamic acid
in pediatric hemorrhagic trauma.binding of plasmin (ogen) to fibrin and the subsequentIntroduction
Trauma is a leading cause of mortality in the pedi-
atric population. In 2008, the American Academy of
Pediatrics noted that trauma accounts for more deaths
than all other causes combined [1]. Bleeding remains the
most preventable cause of death after trauma. A major
recent advance was the recognition that coagulation
defects are greatly responsible for the disproportional
mortality caused by bleeding. Managing coagulation de-
fects has become a forefront issue in trauma and novel
strategies proposed include hemostatic resuscitation,
adoption of massive transfusion protocols and other in-
novations [2], most with little evidence to support them.
The exception is the proposal to administer tranexamic
acid (TXA) to bleeding adult trauma patients.
To date, no medical treatment has been shown to re-
duce mortality in the setting of pediatric trauma; how-
ever, this evidence does exist in adults. Bleeding and
coagulopathy due to trauma are associated with mortal-
ity in both adults and children. Clinical research has
demonstrated a reduction in trauma-related mortality* Correspondence: suzanne.beno@sickkids.ca
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2014with early use of TXA in adult patients in both civilian
and military settings [3,4]. In adult patients with
hemodynamic instability and ongoing bleeding, TXA is
expected to save 1 in 67 lives [3]. There is no scientific
or biological reason to suggest that a similar mortality
benefit will not be seen in pediatric trauma. We feel the
incorporation of TXA into pediatric trauma manage-
ment has the potential to also significantly reduce mor-
tality in children and youths, without increasing adverse
events. This review explores the hematologic differences
and similarities between injured children and adults, and
the idea that TXA may be a novel and promising treat-
ment in pediatric hemorrhagic trauma despite the
current lack of evidence for its use in this setting.
TXA is an antifibrinolytic that reversibly binds to plas-
minogen at the lysine binding site, thus preventing the
degradation of fibrin [5]. It is a generic, inexpensive
medication used to prevent fibrin breakdown and
reduce bleeding in various clinical settings (including
orthopedic and cardiovascular surgery, post-partum
hemorrhage, gastrointestinal hemorrhage, epistaxis, cer-
tain ophthalmologic conditions and other obstetric/gy-
necologic emergencies) [6-9]. The cost per adult trauma
patient is a mere Canadian $11.80 (2 grams), with a cost
per life saved of Canadian $790.60 [3]. Patients are par-
ticularly susceptible to hyperfibrinolysis after traumatic
injury, with 57% having moderate hyperfibrinolysis as
detected by plasmin-antiplasmin complexes, which the-
oretically could be inhibited by TXA [10].Evidence for tranexamic acid in adult trauma
In 2010, CRASH-2 (Clinical Randomization of an Antifi-
brinolytic in Significant Haemorrhage-2) demonstrated
that TXA safely reduces the risk of death in adult (age
≥16 years) trauma. This was the first study to show a
medical treatment for trauma and a reduction in mortal-
ity. This randomized placebo-controlled trial involved
20,211 patients in 40 countries. Adult patients with
unstable vitals (systolic blood pressure <90 mmHg and/
or heart rate >110 beats per minute, or both) or a
high clinical suspicion for significant hemorrhage weretd. The licensee has exclusive rights to distribute this article, in any medium, for
time, the article is available under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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come, in-hospital mortality at 4 weeks, showed a signifi-
cant reduction in risk of death due to bleeding for the
TXA group (risk of death 0.85; 95% confidence interval
0.76 to 0.96; P = 0.004, number needed to treat (NNT)
121) and all-cause mortality for the overall population
(risk of death 0.91; 95% confidence interval 0.85 to 0.97;
P = 0.0035, NNT 67). TXA appeared to have the greatest
impact on reduction of death caused by bleeding in the
severe shock group (admission systolic blood pressure
≤75 mmHg) if administered within the first hour from
injury. Further sub-analysis of CRASH-2 showed that
mortality benefit was greatest when given within 3 hours
of the injury, with suggested increased risk of death
caused by bleeding, but no difference in all-cause mor-
tality, if given later [3,11].
The CRASH-2 trial administered 1 g of TXA over
10 minutes followed by 1 g over 8 hours [3]. Adverse
events have not been published with this dose, but re-
ports exist from other patient populations when much
larger doses are given. In cardiovascular bypass surgery,
extremely high doses (>100 mg/kg) of TXA appear to in-
crease the risk of perioperative seizures [12-15]. There
are also reports of TXA rapid infusion hypotension,
TXA-induced cerebrovascular infarctions and even a
single case report of TXA-induced toxic epidermal
necrolysis [16-18]. Vascular occlusive events were in-
cluded in the secondary outcomes in the CRASH-2 trial,
but there were no significant differences between TXA
and control groups with respect to arterial and venous
thromboembolic events [3]. Systematic reviews have
failed to find a concern regarding adverse events [19-21].
CRASH-2 was a landmark trial involving a large and
diverse study population in many different healthcare
settings. It provides high-level evidence for the wide-
spread global use of TXA in adult trauma patients with
significant hemorrhage. Conversely, the fact that the ma-
jority of sites were in low- and middle-income countries
has drawn criticism for CRASH-2. Concerns include an
over-reliance on results that may not be accurate for pa-
tients cared for in developed comprehensive trauma sys-
tems with lower preventable death rates through access
to blood products, massive transfusion protocols and de-
finitive surgical care. However, Ker and colleagues [22]
found no compelling evidence that geography varied
the effect of TXA on death due to bleeding when
jointly analyzing CRASH-2 trial data, World Health
Organization mortality data, and data from a systematic
review. Lastly, the impressive rarity of thrombotic com-
plications seen in CRASH-2 has sparked concerns that
the possible risk of thromboembolism may have been
underappreciated and might well be higher in hospitals
where these complications would be more actively
sought [23]. While current evidence does not supportthis theory, the focus on thromboembolism merits fur-
ther research.
More recent post hoc analysis showed that administer-
ing TXA to bleeding trauma patients can save an esti-
mated 755 ‘life-years’ per 1,000 trauma patients in the
United Kingdom, with the incremental cost per ‘life-
year’ gained by administering TXA being $64 [24]. An-
other retrospective observational study published in
2011, the Military Application of TXA in Trauma Emer-
gency Resuscitation study, demonstrated an absolute
reduction in both in-hospital and all-cause mortality at
48 hours for the TXA group of 7.6% and 6.5%, respect-
ively. The benefit (13.7%) appeared greatest in the
groups receiving massive transfusion (estimated NNT 7)
[4]. Unlike the pragmatic global approach that CRASH-
2 took, this study population included young healthy sol-
diers receiving advanced first world trauma care for
whom this significant reduction in mortality with TXA
was also found. As a result, standard of care in many
parts of the world involves administering TXA to adult
trauma patients with suspected hemorrhage.
Future studies looking at TXA use in subarachnoid
hemorrhage are already underway and a CRASH-3 trial
is being organized to evaluate the utility and safety of
TXA in isolated traumatic brain injury (TBI) [25].
Tranexamic acid use in pediatrics to date
As in adults, TXA has been well studied in many non-
traumatic pediatric conditions. The numerous studies in
adult and pediatric populations demonstrate similar
benefit from TXA in the perioperative setting. TXA has
successfully reduced blood loss and transfusion require-
ments with a variety of dosing regimens in pediatric
cardiac surgery, scoliosis surgery, and craniosynostosis
repair [26-28]. It has an important role in managing
certain menstrual disturbances and congenital bleeding
disorders, and is effective in treating traumatic hyphema
in children [29]. The adverse effects of TXA in pediat-
rics are very rare but include gastrointestinal effects,
hypotension with rapid intravenous injection, dizziness,
headache, muscle pain and spasms, and postoperative
convulsions in children receiving high doses during
cardiac surgery. The potential risk of thrombosis has not
been identified with large doses in pediatric cardiac
and spinal surgery, and the lower risk in the pediatric
population overall makes this a less concerning issue
[21,27,28].
Trauma: differences and similarities between
adults and children
In adult trauma, hemorrhage is the second overall cause
of death, first preventable cause and first cause of
mortality after arrival to hospital [30]. Recently, there
is increasing appreciation for ‘early trauma-associated
Table 1 Criteria for the use of tranexamic acid in
pediatric trauma
Immediate need for transfusion, with any one of the following
indicating severe shocka
• Systolic blood pressure low (<80 mmHg <5 years and <90 mmHg
≥5 years)
• Poor blood pressure response to crystalloid 20–40 ml/kg
• Obvious significant bleeding
aThe Hospital for Sick Children Massive Hemorrhage Protocol for the use of
tranexamic acid in pediatric trauma. April 2014.
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tion and transfusion. It is estimated that 25% of adult
trauma victims are coagulopathic upon arrival to
the hospital, and when thromboelastography (TEG®) and
rotational thromboelastometry (ROTEM®) are used
diagnostically, up to 6% of these patients already
have massive hyperfibrinolysis. Evidence further shows
that up to 60% may have less intense hyperfibrinolysis
diagnosed by plasmin-antiplasmin complexes, tissue
plasminogen activator and D-dimer levels [31]. It
stands to reason, therefore, that the antifibrinolytic
drug TXA, both theoretically and following high level
evidence, now has a clear role in the injured and
bleeding adult.
Children follow a slightly different pattern of trauma
than adults, with variability existing due to environmen-
tal factors and the broad anatomic, physiologic and de-
velopmental age spectrum that encompasses pediatric
care. Systolic blood pressures in children vary by age,
and hypotension is often seen only once an uncompen-
sated shock state exists (Table 1). The proportion of
blunt to penetrating trauma is higher in children, but
the leading cause of mortality is also traumatic brain in-
jury, a condition known to be associated with coagulopa-
thy in both pediatric and adult populations [32,33].
While the incidence of death from hemorrhage with
traumatic injuries has not been described in children,
hemorrhage remains the most common cause of death
in pediatric solid organ injuries, and blunt thoracoab-
dominal trauma resulting in hemorrhage is the second
leading cause of traumatic death in children [34].Table 2 Tranexamic acid dosing in pediatric trauma
Age Loading dose (administer within 3 hours)
≥12 years::adult
protocol
1 g intravenously over 10 minutes
<12 years 15 mg/kg intravenously over 10 minutes
(maximum dose 1 g)
The Hospital for Sick Children Massive Hemorrhage Protocol for the use of tranexam
Paediatrics and Child Health: Evidence statement - Major trauma and the use of traThe coagulopathic response to trauma in children
Levels of coagulation factors vary by age and maturation,
as does the tendency to clot or bleed, leaving pediatric
trauma patients more susceptible to bleeding when
coagulant maturity lags behind its anticoagulant coun-
terpart. Given the high rates of TBI in the pediatric
population and its possible association with hyperfibri-
nolysis and coagulopathy, the coagulation status of in-
jured children has been addressed in the literature.
Coagulopathy in both pediatric and adult head trauma is
well described, and its published incidence ranges from
15% to 87% [32-34]. In pediatric blunt trauma, coagulop-
athy was reported in 28% of patients by Holmes and col-
leagues [35], with significant coagulopathy occurring in
6% of children and associated with a Glasgow Coma
Scale score ≤13, low systolic blood pressure, open/mul-
tiple fractures, and major tissue wounds. Hendrickson
and colleagues [36] described coagulopathy in pediatric
trauma patients specifically requiring transfusion sup-
port using a combined retrospective review and pro-
spective analysis of 102 children (mean age of 6 years,
injury severity score of 22 and Glasgow Coma Scale
score of 7) presenting to an emergency department over
a 4-year period. Overall, 77% of the patients were coagu-
lopathic on arrival to the emergency department, and
abnormal coagulation parameters remained strongly as-
sociated with mortality even after adjustment for injury
severity score. Coagulopathy was concluded to be preva-
lent, possibly even more common than in adults, in
pediatric trauma patients ill enough to require a transfu-
sion [36]. An evaluation of the role of early coagulopathy
and shock as independent predictors of mortality in chil-
dren with traumatic injuries treated at combat support
hospitals in Iraq and Afghanistan described results simi-
lar to those previously reported for adults, with 27% of
the children demonstrating coagulopathy on admission,
and a higher injury severity score predicting increased
coagulopathy, shock, and ultimately mortality [37].
The role of hyperfibrinolysis in pediatric trauma pa-
tients is not as well established as in adults, although
hypofibrinogenemia has been reported in up to 52%
of children requiring transfusion support [36]. The
experience of using TEG® and ROTEM® technology for
pediatric trauma has been published in case reportsSubsequent dose
1 g intravenous infusion over 8 hours
2 mg/kg/hr intravenous infusion over 8 hours or until bleeding
stops
ic acid in pediatric trauma. April 2014. Adapted from Royal College of
nexamic acid in children [39].
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thrombelastography (rTEG) in 86 children [38]. While
not specifically addressing hyperfibrinolysis, this paper
demonstrated that rTEG provided valuable goal-directed
hemostatic resuscitation data for critically injured
children. The available literature implies that injured
children and adults respond similarly with regards to early
coagulopathy and its association with certain injuries such
as TBI that promote hyperfibrinolysis in the body, the latter
being an important area of research requiring further
exploration.
Tranexamic acid for pediatric trauma
The basis for using TXA in children would appear to be
nearly identical to that for adults, if not more intuitive.
Since children generally have healthier vascular systems
than adults, and with the main concern being thrombo-
embolism, there is no clear reason for enforcing a lower
age limit for this drug. At least in adolescents, where we
can confidently presume their coagulation system has
matured and their injury patterns resemble those of
adults, the role of TXA should be adopted immediately.
In fact, five participants in CRASH-2 were inadvertently
enrolled and later discovered to be under 16 years of age
[3]. The Royal College of Paediatrics and Child Health in
the United Kingdom issued an Evidence statement in
November 2012 entitled ‘Major trauma and the use of
TXA in children’ that proposes the use of TXA for all
children [39]. The dosing consensus reached utilizes the
adult protocol for a 1 g loading dose over 10 minutes
within the first 3 hours post-injury, followed by a 1 g
infusion over 8 hours for children 12 years of age and
older. For children under 12 years of age, the loading
dose was pragmatically estimated at 15 mg/kg (max-
imum dose 1 g) followed by an infusion of 2 mg/kg/hour
for at least 8 hours or until the bleeding stops [39]
(Table 2). The doses of TXA used for trauma are signifi-
cantly lower than the published doses in use for
pediatric cardiac, spinal and craniofacial surgery, and
even at these doses adverse events are rare. The emer-
ging concern of post-administration seizures has not
been reported for the dose used in trauma.
Use of tranexamic acid in pediatric hemorrhagic
trauma
According to best available evidence in 2014, TXA sig-
nificantly decreases mortality in bleeding trauma pa-
tients 16 years of age and older without significantly
increasing prothrombotic complications if administered
within 3 hours of injury. Currently, there is no evidence
of benefit in patients with TBI, and results from
CRASH-3 should guide treatment in this area. Early
treatment with TXA is recommended in adult trauma
patients at risk for significant hemorrhage, patients beingtransfused, and particularly those requiring massive
transfusion or who have an elevated baseline risk of
death [40].
While the evidence specifically for TXA in pediatric
trauma is not yet available, we feel that TXA should be
considered for use in adolescent trauma patients in the
same dosing regimen and indications as used in adults.
Given the consistency in coagulation response to tissue
injury across age spectrums, we feel that young children
with hemodynamic instability and ongoing risk for
hemorrhage would also benefit from TXA while recog-
nizing this specifically as an area in need of further re-
search. The adoption and use of this inexpensive and
cost-effective therapy may reach only a small percentage
of pediatric trauma patients. However, without antici-
pated risk, in children requiring transfusion support fol-
lowing trauma, TXA plausibly holds similar or greater
benefit for mortality reduction than has already been
demonstrated in adults. Denying injured children TXA
due to the lack of pediatric trauma trial evidence in this
indication is likely shortsighted and unnecessary given
the ample clinical evidence in other pediatric settings,
the excellent safety record of the drug, and the clear
mortality benefit seen in adult trauma.
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